These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3064907)

  • 1. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension.
    Board AW; Perry VP; Shepperson BE; Nyman CE; Carchman SH
    Clin Ther; 1988; 10(6):761-75. PubMed ID: 3064907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG; Bloxham CA; Walker JM
    Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antihypertensive therapy with guanfacine.
    Szám I; Holló J
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):388-92. PubMed ID: 6749702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and tolerance of the antihypertensive agent guanfacine.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):170-4. PubMed ID: 6370876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Estulic in the long-term treatment of hypertension].
    Rhomberg F
    Schweiz Med Wochenschr; 1980 Dec; 110(50):1922-4. PubMed ID: 6782668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic effects of guanfacine in essential hypertension.
    Feldstein CA; Cohen AA; Sabaris RP; Burucúa JE
    Clin Ther; 1984; 6(3):325-34. PubMed ID: 6373009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new centrally action antihypertensive agent guanfacine (BS 100-141).
    Dubach UC; Huwyler R; Radielovic P; Singeisen M
    Arzneimittelforschung; 1977; 27(3):674-6. PubMed ID: 326262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study].
    Rhomberg F; Widler J
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1967-8. PubMed ID: 7036334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ; Laszt A; Paran E; Ben Ari J; Goren Y; Modan M
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract]   [Full Text] [Related]  

  • 16. [Controlled doubleblind study on dose-effect relationship of guanfacine a long-acting hypotensive guanidine derivative (author's transl)].
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G
    Arzneimittelforschung; 1980; 30(6):1005-7. PubMed ID: 6998487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
    Rosenthal J; Jäger H
    MMW Munch Med Wochenschr; 1980 Jan; 122(4):137-40. PubMed ID: 6767938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing survey of the effects of an atenolol/chlorthalidone combination in the treatment of hypertension.
    Maxwell MH; Garrett BN; Saunders E; Schnaper H
    Clin Ther; 1987; 9(4):380-9. PubMed ID: 3607820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of chronic guanfacine administration on high plasma vasopressin levels in essential hypertension.
    Berkman K; Tözün N; Taga Y; Dedeoğlu A; Onat F; Bekiroğlu N
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):67-71. PubMed ID: 2407671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.